145 related articles for article (PubMed ID: 9479580)
1. Immunologic approaches to inhibiting cell-surface-residing oncoproteins in human tumors.
O'Rourke DM; Greene MI
Immunol Res; 1998; 17(1-2):179-89. PubMed ID: 9479580
[TBL] [Abstract][Full Text] [Related]
2. Principles of receptor-based inhibition of erbB family receptor kinases: prospects for new therapies for human cancers.
O'Rourke DM; Zhang X; Greene MI
Proc Assoc Am Physicians; 1997 May; 109(3):209-19. PubMed ID: 9154637
[TBL] [Abstract][Full Text] [Related]
3. ErbB-directed immunotherapy: antibodies in current practice and promising new agents.
Friedländer E; Barok M; Szöllosi J; Vereb G
Immunol Lett; 2008 Mar; 116(2):126-40. PubMed ID: 18201769
[TBL] [Abstract][Full Text] [Related]
4. Clinical and prognostic significance of the expression of the c-erbB-2 and c-erbB-3 oncoproteins in primary and metastatic malignant melanomas and breast carcinomas.
Bodey B; Bodey B; Gröger AM; Luck JV; Siegel SE; Taylor CR; Kaiser HE
Anticancer Res; 1997; 17(2B):1319-30. PubMed ID: 9137492
[TBL] [Abstract][Full Text] [Related]
5. Intracellular expression of a single-chain antibody directed to the EGFR leads to growth inhibition of tumor cells.
Jannot CB; Beerli RR; Mason S; Gullick WJ; Hynes NE
Oncogene; 1996 Jul; 13(2):275-82. PubMed ID: 8710366
[TBL] [Abstract][Full Text] [Related]
6. Biological studies and potential therapeutic applications of monoclonal antibodies and small molecules reactive with the neu/c-erbB-2 protein.
Dougall WC; Greene MI
Cell Biophys; 1994; 24-25():209-18. PubMed ID: 7736525
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of a naturally occurring EGFR oncoprotein by the p185neu ectodomain: implications for subdomain contributions to receptor assembly.
O'Rourke DM; Nute EJ; Davis JG; Wu C; Lee A; Murali R; Zhang HT; Qian X; Kao CC; Greene MI
Oncogene; 1998 Mar; 16(9):1197-207. PubMed ID: 9528862
[TBL] [Abstract][Full Text] [Related]
8. Anti-ErbB-2 monoclonal antibodies and ErbB-2-directed vaccines.
Yip YL; Ward RL
Cancer Immunol Immunother; 2002 Jan; 50(11):569-87. PubMed ID: 11807621
[TBL] [Abstract][Full Text] [Related]
9. Significance of the c-erbB family of receptor tyrosine kinases in metastatic cancer and their potential as targets for immunotherapy.
Eccles SA; Modjtahedi H; Box G; Court W; Sandle J; Dean CJ
Invasion Metastasis; 1994-1995; 14(1-6):337-48. PubMed ID: 7657527
[TBL] [Abstract][Full Text] [Related]
10. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors.
Klapper LN; Kirschbaum MH; Sela M; Yarden Y
Adv Cancer Res; 2000; 77():25-79. PubMed ID: 10549355
[TBL] [Abstract][Full Text] [Related]
11. Interaction of the neu/p185 and EGF receptor tyrosine kinases: implications for cellular transformation and tumor therapy.
Dougall WC; Qian X; Greene MI
J Cell Biochem; 1993 Sep; 53(1):61-73. PubMed ID: 7901229
[TBL] [Abstract][Full Text] [Related]
12. ErbB receptors and signaling pathways in cancer.
Hynes NE; MacDonald G
Curr Opin Cell Biol; 2009 Apr; 21(2):177-84. PubMed ID: 19208461
[TBL] [Abstract][Full Text] [Related]
13. New insights into anti-HER-2 receptor monoclonal antibody research.
Kumar R; Mandal M; Vadlamudi R
Semin Oncol; 2000 Dec; 27(6 Suppl 11):84-91; discussion 92-100. PubMed ID: 11236033
[TBL] [Abstract][Full Text] [Related]
14. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
Motoyama AB; Hynes NE; Lane HA
Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
[TBL] [Abstract][Full Text] [Related]
15. Identification of p185neu sequences required for monoclonal antibody- or ligand-mediated receptor signal attenuation.
Qian X; O'Rourke DM; Drebin J; Zhao H; Wang Q; Greene MI
DNA Cell Biol; 1997 Dec; 16(12):1395-405. PubMed ID: 9428788
[TBL] [Abstract][Full Text] [Related]
16. Cell surface density of p185(c-erbB-2) determines susceptibility to anti-p185(c-erbB-2)-ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170(EGFR)-RTA in ovarian cancer cells.
Dean GS; Pusztai L; Xu FJ; O'Briant K; DeSombre K; Conaway M; Boyer CM; Mendelsohn J; Bast RC
Clin Cancer Res; 1998 Oct; 4(10):2545-50. PubMed ID: 9796989
[TBL] [Abstract][Full Text] [Related]
17. The ErbB/HER family of receptor tyrosine kinases: A potential target for chemoprevention of epithelial neoplasms.
Kirschbaum MH; Yarden Y
J Cell Biochem Suppl; 2000; 34():52-60. PubMed ID: 10762015
[TBL] [Abstract][Full Text] [Related]
18. The ErbB/HER receptor protein-tyrosine kinases and cancer.
Roskoski R
Biochem Biophys Res Commun; 2004 Jun; 319(1):1-11. PubMed ID: 15158434
[TBL] [Abstract][Full Text] [Related]
19. Immune responses to all ErbB family receptors detectable in serum of cancer patients.
Bei R; Masuelli L; Moriconi E; Visco V; Moretti A; Kraus MH; Muraro R
Oncogene; 1999 Feb; 18(6):1267-75. PubMed ID: 10022808
[TBL] [Abstract][Full Text] [Related]
20. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.
Petit AM; Rak J; Hung MC; Rockwell P; Goldstein N; Fendly B; Kerbel RS
Am J Pathol; 1997 Dec; 151(6):1523-30. PubMed ID: 9403702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]